Ibodutant clinical trials
How each study uses ibodutant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses ibodutant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- 52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)TerminatedPhase 3Menarini GroupNCT02120027Written as Ibodutant 10 mg
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)CompletedPhase 3Menarini GroupNCT02107196Written as Ibodutant 10 mg
- 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)WithdrawnPhase 3Menarini GroupNCT02320318Written as Ibodutant 10 mg
- Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)CompletedPhase 2Menarini GroupNCT01303224Written as Ibodutant
- Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)CompletedPhase 2Menarini GroupNCT00761007Written as Ibodutant
Codes
What other systems call ibodutant · ClinicalTrials.gg INT005790
- MeSH (NLM) C556791ibodutantOne source NLM
- UNII (FDA) 1H7RSQ28BJIBODUTANTConfirmed FDA, NLM, Wikidata
- Wikidata Q5984345ibodutantConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166502IbodutantOne source FDA
- DrugBank DB12042One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C556791 | ibodutant | One source NLM |
| UNII (FDA) | 1H7RSQ28BJ | IBODUTANT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5984345 | ibodutant | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166502 | Ibodutant | One source FDA |
| DrugBank | DB12042 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.